Skip to main content

Table 2 Risk of congenital heart defects among exposed to SSRIs versus unexposed

From: Increased risk of severe congenital heart defects in offspring exposed to selective serotonin-reuptake inhibitors in early pregnancy – an epidemiological study using validated EUROCAT data

 

Unexposed (n = 71435)

Exposed to any SSRI (n = 845)

 

n (%)

n (%)

OR (95% CI)

AOR¤(95% CI)

Congenital heart defects*

535 (0.75)

11 (1.30)

1.75 (0.96-3.19)

1.64 (0.89-3.00)

VSD

329 (17.88)

4 (16.67)

1.02 (0.38-2.76)

0.94 (0.35-2.53)

ASD

94 (5.11)

3 (12.50)

2.70 (0.85-8.55)

2.82 (0.88-9.04)

Pulmonary valve stenosis

52 (2.83)

2 (8.33)

3.26 (0.79-13.39)

3.47 (0.83-14.50)

Severe CHD

123 (0.17)

6 (0.71)

4.15 (1.82-9.44)

4.03 (1.75-9.26)

  1. SSRI, selective serotonin-reuptake inhibitor. CHD, congenital heart defects. VSD, ventricular septal defects. ASD, atrial septal defects. NE, no estimate. OR, odds ratio. AOR, adjusted odds ratio.
  2. *Congenital heart defects include both non-severe and severe CHD.
  3. Estimates are presented as ORs with 95% confidence intervals (95% CIs).
  4. ¤Multivariable Logistic Regressions are adjusted for maternal age, year of conception, use of antiepileptics and/or insulin during first trimester.
Back to article page

BMC Pregnancy and Childbirth

ISSN: 1471-2393

Contact us